Complex formulation strategies to overcome the delivery hurdles of lapatinib in metastatic breast cancer
Authors:
- Nidhi SinghNSNidhi Singh
- Kolimi Prashanth ReddyKRKolimi Prashanth Reddy
- Priyanka DasPDPriyanka Das
- Bhamare Kumudini KishorBKBhamare Kumudini Kishor
- Pallab DattaPDPallab Datta
- 3 March 2023
- journal article
- review article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 82
Abstract
No abstract availableKeywords
This publication has 104 references indexed in Scilit:
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesExpert Review of Anticancer Therapy, 2011
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancerNature Medicine, 2010
- A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid MalignanciesClinical Cancer Research, 2009
- Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell linesAnti-Cancer Drugs, 2009
- Nanoparticles evading the reticuloendothelial system: Role of the supported bilayerBiochimica et Biophysica Acta (BBA) - Biomembranes, 2009
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticlesJournal of Controlled Release, 2008
- Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2Cancer Research, 2008
- Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the BrainJNCI: Journal of the National Cancer Institute, 2008
- LapatinibNature Reviews Drug Discovery, 2007